Millennium Management LLC Trims Stake in Celcuity Inc. (NASDAQ:CELC)

Millennium Management LLC cut its holdings in Celcuity Inc. (NASDAQ:CELC - Free Report) by 74.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,660 shares of the company's stock after selling 113,721 shares during the period. Millennium Management LLC owned about 0.11% of Celcuity worth $519,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its holdings in shares of Celcuity by 42.9% in the fourth quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company's stock worth $35,062,000 after purchasing an additional 803,575 shares during the period. Bleakley Financial Group LLC purchased a new stake in shares of Celcuity during the fourth quarter worth about $146,000. Ameriprise Financial Inc. increased its stake in shares of Celcuity by 45.9% during the fourth quarter. Ameriprise Financial Inc. now owns 447,171 shares of the company's stock valued at $5,853,000 after buying an additional 140,642 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Celcuity by 16.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock valued at $258,000 after acquiring an additional 2,756 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Celcuity by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company's stock worth $21,624,000 after acquiring an additional 24,429 shares during the period. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Trading Up 0.6%

Shares of NASDAQ CELC traded up $0.07 during trading hours on Thursday, hitting $12.56. 134,533 shares of the company traded hands, compared to its average volume of 290,431. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 12 month low of $7.58 and a 12 month high of $19.77. The stock has a market capitalization of $475.60 million, a price-to-earnings ratio of -4.81 and a beta of 0.37. The company's 50 day moving average price is $10.62 and its 200 day moving average price is $11.31.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, equities research analysts anticipate that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Celcuity in a research note on Monday, May 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 price objective on shares of Celcuity in a research report on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Celcuity presently has an average rating of "Buy" and an average price target of $30.80.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.